The sheer number of novel oncology approvals by the US Food & Drug Administration is an astonishing testament to the pace of scientific breakthroughs and investment by biopharma companies in anti-cancer therapies.
US FDA’s Three Review Speeds: Standard, Priority – And Oncology
FDA’s oncology review team likes to do things its own way – and at its own hyper fast pace.
